IRIS
CESARO, ARTURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.665
AS - Asia 2.411
NA - Nord America 1.550
SA - Sud America 458
AF - Africa 39
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 7.126
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.507
RU - Federazione Russa 1.398
SG - Singapore 879
CN - Cina 588
IE - Irlanda 484
HK - Hong Kong 399
BR - Brasile 379
IT - Italia 294
VN - Vietnam 164
DE - Germania 144
KR - Corea 144
GB - Regno Unito 120
IN - India 96
AR - Argentina 39
FR - Francia 36
AT - Austria 26
GR - Grecia 25
FI - Finlandia 22
SE - Svezia 22
UA - Ucraina 22
BD - Bangladesh 21
MX - Messico 21
TR - Turchia 20
ID - Indonesia 17
BE - Belgio 16
JP - Giappone 16
CA - Canada 15
NL - Olanda 15
IQ - Iraq 13
EG - Egitto 11
EC - Ecuador 10
PK - Pakistan 10
ZA - Sudafrica 10
CO - Colombia 9
ES - Italia 8
LT - Lituania 7
PL - Polonia 7
VE - Venezuela 7
MA - Marocco 6
IR - Iran 5
TH - Thailandia 5
UZ - Uzbekistan 5
PA - Panama 4
TN - Tunisia 4
UY - Uruguay 4
CL - Cile 3
DK - Danimarca 3
IL - Israele 3
KE - Kenya 3
KZ - Kazakistan 3
NP - Nepal 3
PE - Perù 3
PY - Paraguay 3
SA - Arabia Saudita 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
EU - Europa 2
JM - Giamaica 2
JO - Giordania 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GH - Ghana 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
RO - Romania 1
SY - Repubblica araba siriana 1
Totale 7.126
Salva come PNG Salva come JPEG
Città #
Dublin 475
Moscow 438
Hong Kong 399
Santa Clara 356
Singapore 313
Chandler 237
Hefei 170
Seoul 143
New York 102
Ashburn 78
The Dalles 77
Naples 69
Beijing 68
Bengaluru 68
Ho Chi Minh City 61
Princeton 51
Roxbury 51
Jacksonville 37
Bremen 34
Nuremberg 31
Cambridge 30
Hanoi 30
Los Angeles 25
São Paulo 24
Dallas 23
Medford 23
Des Moines 22
Falkenstein 21
Munich 19
Milan 17
Boardman 16
Brussels 16
Aversa 14
Mexico City 13
Rio de Janeiro 13
Ann Arbor 12
Helsinki 12
Guangzhou 11
Hyderabad 11
Wilmington 11
Nanjing 10
Vienna 9
Belo Horizonte 8
Campinas 8
Curitiba 8
Ercolano 8
Sivas 8
Amsterdam 7
Cairo 7
Caserta 7
Da Nang 7
Dhaka 7
Frankfurt am Main 7
Jinan 7
London 7
Rome 7
Baghdad 6
Brasília 6
Salerno 6
Turin 6
Bangkok 5
Bologna 5
Columbus 5
Haiphong 5
Hải Dương 5
Islamabad 5
Jakarta 5
Johannesburg 5
Lappeenranta 5
Osasco 5
Porto Alegre 5
San Francisco 5
Stockholm 5
Thái Bình 5
Toronto 5
Boston 4
Bresso 4
Brooklyn 4
Buenos Aires 4
Campo Grande 4
Caraglio 4
Chicago 4
Florence 4
Guarulhos 4
Guayaquil 4
Houston 4
Istanbul 4
Montreal 4
Porto Velho 4
Salvador 4
Shenyang 4
Tashkent 4
Turku 4
Vicenza 4
Warsaw 4
Woodbridge 4
Xi'an 4
Zhengzhou 4
Ankara 3
Bari 3
Totale 3.940
Salva come PNG Salva come JPEG
Nome #
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 115
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 108
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 106
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 106
Advanced Heart Failure in Special Population—Pediatric Age 105
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 101
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 98
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 97
null 93
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 92
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 90
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 89
Diagnosis and Management of Cardiovascular Involvement in Fabry Disease 89
Cardiac involvement in systemic sclerosis: 'early diagnosis-early management' approach 87
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 87
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 84
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 83
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 81
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 78
Early-onset MINOCA: Prognostic implications and considerations for practice 78
Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent 76
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 76
Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge 76
SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes 76
Coronary stent thickness: thinner is (always) better for all lesions? 75
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 74
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 74
The Biological Role of Vitamins in Athletes’ Muscle, Heart and Microbiota 74
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 73
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 73
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 73
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 72
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 72
SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction 72
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 72
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes 72
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 71
[Long COVID: nosographic aspects and clinical epidemiology] 70
The Role of Genetic Testing in Patients with Heritable Thoracic Aortic Diseases 70
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 69
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 69
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 69
The Impact of Physical Exercise on Obesity in a Cohort of Southern Italian Obese Children: Improvement in Cardiovascular Risk and Immune System Biomarkers 67
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 66
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque 66
Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT) 66
Multimodality Imaging in Arrhythmogenic Left Ventricular Cardiomyopathy 65
Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis? 65
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 64
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor 63
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 63
Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): A meta-analysis 63
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 62
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 61
Ipercolesterolemia e referti di laboratorio: documento congiunto della Società Italiana di Cardiologia (SIC) e Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica - Medicina di Laboratorio (SIBioC) 61
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 61
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 60
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 59
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 59
How has COVID-19 impacted the care of patients with acute coronary syndromes? 58
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 58
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 58
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 57
The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review 57
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry 57
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 56
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 56
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 55
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 55
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 55
Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve 55
The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia 53
Laboratory medicine: health evaluation in elite athletes 53
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 53
Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention 52
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial 52
Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention 51
Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein? 50
Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry) 50
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials 50
Reply to SGLT-2 inhibitors: Post-infarction interventional effects 49
Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis 49
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 49
Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology 49
Circulating culprit or therapeutic bullseye: lipoprotein(a) in cardiovascular risk assessment and novel therapeutic prospects 49
Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease 48
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey 48
Geographic variations in percutaneous versus surgical coronary revascularization: A global perspective from the SYNTAXES trial 47
Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol 47
A pragmatic approach for thrombotic prevention after acute coronary syndromes 46
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia 45
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 45
Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism 45
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 45
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain 43
Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis 43
Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter 43
Rheumatic mitral stenosis in a 28-week pregnant woman treated by mitral valvuoplasty guided by low dose of radiation: a case report and brief overview 42
Beyond the left ventricle: Why the right heart matters in Takotsubo syndrome 41
Artificial intelligence in cardiovascular prevention: new ways will open new doors 40
Totale 6.590
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.608
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.608
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202193 0 0 0 0 0 0 34 2 11 7 30 9
2021/2022430 9 3 8 17 104 10 10 41 9 55 37 127
2022/2023863 84 56 19 59 77 46 2 57 428 5 14 16
2023/2024513 28 17 20 24 129 111 19 12 4 29 13 107
2024/20251.804 8 13 2 54 251 207 231 170 259 276 172 161
2025/20263.526 359 526 487 418 678 1.058 0 0 0 0 0 0
Totale 7.396